Korea United Pharm Inc

Korea United Pharm Inc maintains a strong liquidity position, with a current ratio of 5.63 and cash and equivalents of 40,270.45 million KRW. The company's debt-to-equity ratio is 0.03, indicating a conservative capital structure with minimal leverage. Free cash flow stands at 17,547.74 million KRW, supporting operational flexibility and potential reinvestment. Profitability metrics show a return on equity (ROE) of 8.43% and a return on assets (ROA) of 7.37%, both exceeding the typical thresholds for the pharmaceutical industry. Operating income of 49,480.69 million KRW and a gross profit of 160,595.07 million KRW reflect strong cost control and pricing power. These figures align with the industry's emphasis on high-margin product development and distribution. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification beyond South Korea. This concentration may expose the company to regional economic and regulatory risks, though it also allows for focused operational efficiency. Looking ahead, Korea United Pharm Inc is projected to maintain stable revenue growth, supported by its strong cash flow and low debt burden. Analysts have assigned a mean price target of 30,000 KRW, with a mean recommendation of 1.50, indicating a generally positive outlook. Risk factors for the company are currently low, with no immediate liquidity or dilution concerns. The company's low debt-to-equity ratio and strong cash reserves mitigate financial risk. Additionally, there are no recent filings or transcripts indicating significant operational or strategic shifts. Recent investor relations data shows a consensus of one strong-buy and one buy recommendation, with no hold or sell ratings. This suggests a favorable market perception of the company's fundamentals and growth prospects.